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Abstract  
Analysis of 226 exome-sequenced UK cases of familial amyotrophic lateral sclerosis (ALS) and 
frontotemporal dementia (FTD) identified two individuals that harboured a P497H and P506S 
UBQLN2 mutation respectively (n=0.9%). The P506S index case presented with behavioral 
variant frontotemporal dementia (FTD) at the age of 54, then progressed to ALS surviving three 
years. Three sons presented with a) slowly progressive pure spastic paraplegia with an onset at 
25 years and b) ALS with disease onset of 25yrs and survival of two years respectively and c) 
ALS presenting symptoms at 26yrs of age. Analysis of post mortem tissue from the index case 
revealed frequent neuronal cytoplasmic UBQLN2 positive inclusions in the dentate gyrus and 
TDP-43 positive neuronal cytoplasmic inclusions in the frontal and temporal cortex and granular 
cell layer of the dentate gyrus of the hippocampus. The presentation of multiple intrafamilial 
phenotypes suggests P506S to be pleiotropic. Furthermore, a comprehensive analysis of 
published UBQLN2 mutations demonstrated that only proline-rich domain mutations contribute 
to a significantly earlier age of onset in male patients (p=0.0026). 
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Introduction 
Amyotrophic Lateral Sclerosis (ALS) is a progressive, neurodegenerative disease with an 
average age at onset of ~60 years and mean survival of ~3-5 years. Most ALS+/-FTD cases are 
apparently sporadic ALS (SALS) but ~10% of patients have a family history indicating 
incompletely penetrant autosomal dominant inheritance. Mutations in superoxide dismutase 1 
(SOD1), TAR DNA-binding protein (TARDBP), fused in sarcoma (FUS), and the G4C2 
expansion on chromosome 9p (C9ORF72) account for approximately 50% of European FALS 
cases (Smith et al., 2013). Mutations in UBQLN2 were originally identified in X-linked kindreds 
with ALS and FTD accounting for a modest proportion of FALS cases (2.7% in Deng et al., 
2011). A recent large-scale burden analysis of exome sequencing data has independently verified 
the significance of UBQLN2 mutations in FALS (Kenna et al., 2016). Interestingly, UBQLN2 
mutations are associated with a wide range of neurodegenerative phenotypes (ALS+/-FTD, FTD, 
Primary Lateral Sclerosis (PLS) and Hereditary Spastic Paraplegia (HSP)), (Vengoechea et al., 
2013). Here we present further evidence of this phenomenon by the presentation of striking intra-
familial phenotypic variation in a family carrying a p.P506S UBQLN2 mutation supported by 
patient specific neuropathology demonstrating UBQLN2 positive aggregates.  
 
1. Methods 
 
1.1 Participants 
The DNA of 226 FALS patients was exome sequenced as part of an existing novel ALS gene 
hunting project. All cases were from the UK, and sourced from local ALS clinics and the MNDA 
DNA Bank. All patients were diagnosed with ALS according to El Escorial criteria (Brooks et 
al., 2000) and full consent was obtained for research purposes. All cases were devoid of 
mutations in TARDBP, SOD1, FUS, OPTN, VCP, TBK1, MATR3, PFN1, TUBA4A, ANXA11, 
CHCHD10, NEK1, CCNF, C21ORF2, KIF5A, and the C9ORF72 intronic GGGGCC expansion. 
DNA from 500 UK SALS cases were screened by Sanger sequencing for mutations in the 
proline rich encoding region (residues 491 to 526) of UBQLN2 (NM_013444), which is a 
mutation hotspot. 
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1.2 Genetic analysis 
The exomes of the 226 FALS cases were captured using the Roche Nimblegen seqcap EZ exome 
probeset v3.0 and sequenced with a HiSeq2000 sequencing system (Illumina, Guy’s campus, 
King’s College London, UK). Exome sequencing paired-end FASTQ files were aligned to the 
hg19 human reference using NovoCraft Novoalign, and variants called with samtools v1.1 
mpileup. Validation and direct sequencing of UBQLN2 was performed by amplification of the 
entire single exon gene with 1 PCR reaction and Sanger sequencing with nested internal primers. 
PCR products were Sanger sequenced using Big-Dye V1.1 and products run on an ABI3130 
Genetic Analyzer (Applied Biosystems Pty Ltd, Warrington). Mutations were identified using 
Sequencher Version 5.1. Primer sequences and amplification conditions are available upon 
request. Conservation of UBQLN2 was examined by ClustalW alignment 
(http://www.ebi.ac.uk/Tools/msa/clustalo/).  
1.3 Immunohistochemistry 
In brief, sections of 7µm thickness were cut from paraffin-embedded tissue blocks, then 
deparaffinised in xylene. Endogenous peroxidases were blocked by immersion in 2.5% H2O2 in 
methanol and immunohistochemistry performed. To enhance antigen retrieval sections were kept 
in citrate buffer (pH 6) for 10 minutes following microwave treatment. After blocking in normal 
rabbit serum (1:10, DAKO, UK) in Tris-buffered saline (pH 7.6), anti-Ubiquilin2 antibody 
(1:500, Abnova) was applied overnight at 4oC. Following washes, sections were incubated with 
biotinylated secondary antibody (rabbit anti-mouse, 1:100, DAKO, UK), followed by 
avidin:biotinylated enzyme complex (Vectastain Elite ABC kit, Vector Laboratories, 
Peterborough, UK). Finally sections were incubated for 10-15 min with 0.5 mg/mL 3,3′-
diaminobenzidine chromogen (Sigma-Aldrich Company Ltd, Dorset, UK) in TBS containing 
0.05% H2O2. Sections were counterstained with Harris’ haematoxylin and immunostaining was 
analysed using a light microscope (Leica, Wetzlar, Germany). 
1.4 Statistics 
The significance between the means for the ages of females and males carrying UBQLN2 
mutations in this and published studies were calculated using a two-tailed t-test with the Graph-
pad online calculator (https://www.graphpad.com/quickcalcs/ttest1/). 
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2. Results 
We performed exome sequencing in 226 FALS and identified two UBQLN2 mutations; P497H 
and P506S in two FALS (0.88% frequency), both located in the proline rich region and 
previously described (Gellera et al. 2013, Vengoechea et al. 2013, Deng et. al., 2011, Teyssou 
et.al 2017) (Fig 1A, 1B). Both mutations were absent from 1000 local UK controls and online 
exome control databases (1000 Genomes, Exome Variant Server n=6503 and ExAC n=60,706). 
The male index patient harbouring the P497H mutation presented at 39 years of age with 
symptoms in the fingers of the right hand, slowly progressing to involve both arms, which 
demonstrated fasciculations and profound wasting. There were no bulbar features. He died 8 
years after disease onset with no evidence of FTD (Fig 1A, III.5). In contrast, his mother (II.8) 
presented with bulbar symptoms at 69 years of age and survived only two years following 
disease onset. The proband’s two maternal aunts (II.4, II.6) were also affected and died in their 
forties. An affected uncle (II.3) presented at 24 years of age, and a male affected cousin (III.1) 
presented at 40 years. No additional clinical details were available to further characterize this 
kindred and no DNA was available from other affected/unaffected family members for 
segregation testing.  
The proband of the family harbouring the P506S mutation (Fig 1B, II.2) was diagnosed with 
FTD at age 54 with gradual behavioural and personality changes over a period of two years. A 
year after her initial diagnosis, she clearly showed signs of ALS with muscle wasting, 
fasciculation and exaggerated reflexes in the cranial nerve, upper limb territories and lower limbs 
alone being the first symptoms. The duration of disease was three years. Two of her sons 
presented with distinct motor syndromes. III.2 was diagnosed with HSP at age 25 and is still 
alive. III.3 was diagnosed with early onset ALS and died at the age of 27 years. Their half-
brother, III.1, was also diagnosed with pure ALS at 26 years of age. All affected members of the 
kindred carry the P506S change. Both the P497H and P506S mutations are located within the 
proline rich domain (PXX) and fully conserved within mammals (Figs 1C and 1D).  
Post mortem tissue was available from the P506S ALS/FTD proband (Fig 1B, II:2). Staining 
with a UBQLN2 antibody showed frequent neuronal cytoplasmic UBQLN2 positive inclusions 
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in the dentate gyrus (Fig 2A) and scattered neuronal cytoplasmic inclusions and neurites in the 
neocortex.  Unfortunately, spinal cord tissue was not available to confirm presence of motor 
neurone damage. Thirteen cases of ALS, FTLD-ALS, and FTLD-TDP devoid of known 
ALS/FTD mutations were also stained with the UBQLN2 antibody. The density and distribution 
of the staining was markedly variable (data not shown), as has been described previously 
(Brettschneider et al 2012). Some cases had more, and some less extensive staining than the 
P506S ALS/FTD proband (Fig 2B). No UBQLN2 inclusions were seen in the cerebral tissue 
from the control cases (Fig 2C). Histological examination of the P506S proband also showed 
frequent TDP-43 positive neuronal cytoplasmic inclusions (NCIs) in the frontal and temporal 
cortices and granular cell layer of the dentate gyrus of the hippocampus (Fig 2D-E). TDP-43 
positive neuronal cytoplasmic inclusions were also observed in the XIIth cranial nerve nucleus 
(Fig 2F). Deposition of TDP-43 was also noticed in the putamen, thalamus and amygdala. The 
motor cortex revealed only occasional TDP-43 positive NCIs. This case of TDP-43 pathology is 
classified as most closely matching histological type B as there were frequent granular 
intraneuronal cytoplasmic TDP-43 inclusions but only occasional neurites, which are frequently 
observed in cases of FTD and ALS.  
As two mutations were identified in the proline rich domain, we investigated this hotspot further 
by Sanger Sequencing this domain in 500 UK SALS cases. However, no mutations were 
detected.  Interestingly, the male UBQLN2 carriers from our P497H and P506S kindreds (Fig 2A 
and B) had a significantly earlier age of onset compared to females (females=54,69, 
males=25,26,39,40 t=3.8069, p=0.0190). This suggests that due to the lack of a wild-type allele 
(UBQLN2 is located on the X chromosome), male UBQLN2 mutation carriers may have elevated 
disease penetrance and therefore manifest ALS earlier than female heterozygous UBQLN2 
mutations carriers. This has been previously observed in several UBQLN2 screening studies 
(Deng et al., 2011; Vengoechea et al., 2013, Teyssou et.al 2017). With these observations, we 
therefore surveyed all published ALS+/-FTD cases harbouring UBQLN2 mutations to address 
this question. Supplementary Table 1 lists all index cases with UBQLN2 mutations in ALS+/-
FTD cases published to date. Ten of the 28 different amino acid changes observed reside in the 
PXX domain and most of the index cases are Caucasian. 56% (24/43) of the cases were female 
and demonstrated a significantly later age of onset than males (females: mean = 51.75 years, 
males: mean = 38.5 years, t = 2.6110, p = 0.0126). In particular, when cases harbouring proline 
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rich domain mutations were analysed in isolation, the age of onset between the two genders was 
more pronounced and significantly reduced in males (females: mean = 53.56 years, males: mean 
= 34.38 years, t = 3.6053, p = 0.0026). Interestingly, within the proline rich domain, with the 
exception of variants P509S and P525S that are heterozygous in ExAC in approximately 
1:10,000 and 1:1,000 Europeans respectively, all other ALS linked proline rich domain variants 
are novel. Moreover, in gnomAD, while P509S is again found 1:10,000 Europeans, the P525S 
variant is frequently present in Ashkenazi Jews, with around 1% of the population carrying the 
common variant. 
 
Discussion 
We have identified two UBQLN2 mutations, P497H and P506S that are absent from ExAC and 
local UK controls in a cohort of 226 ALS patients (0.88% frequency). Although previously 
identified, this report confirms that both variants are common, recurrent UBQLN2 mutations that 
occur in ALS patients from distinct populations, emphasizing the requirement for routine 
diagnostic screening (Deng et al., 2011; Vengoechea et al., 2013; Gellera et al., 2013; Özoğuz et 
al., 2015). Significantly though, we demonstrate here that the P506S mutation results in 
UBQLN2 positive aggregates in post-mortem tissue. This is the first neuropathological report of 
a patient harbouring a UBQLN2 P506S mutation that adds to the characterized list of proline rich 
mutations in ALS/FTD tissue (Deng et al., 2011; Williams et al., 2012; Scotter et al., 2016). 
Furthermore, this provides additional evidence of aggregation prone mutations located in the 
proline rich domain of Ubiquilin 2; highlighting the significance of this region. Furthermore, we 
observed striking intra-familial clinical phenotypic heterogeneity of individuals possessing the 
P506S mutation. Firstly the proband P506S mother presenting initially with FTD and then 
subsequently with ALS, then her two sons demonstrating rapidly progressive, young onset ALS 
in contrast to another son with early onset HSP. This intra-familial phenotypic difference due to 
P506S has previously been reported (Vengoechea et al., 2013, Teyssou et.al 2017). Interestingly, 
the P506 residue in particular when mutated, is highly prone to manifesting multiple phenotypes 
as Teyssou et.al also reported a P506A carrying kindred with a predominant upper motor neuron 
phenotype that progressed, in time, to ALS. In light of this observed reduction in age of onset, a 
comprehensive analysis of published data, suggests that the proline-rich domain UBQLN2 
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mutations in particular account for the significant earlier disease onset in males. However, why 
male carriers with the same P506S mutation would present with either ALS or HSP is currently 
unexplainable. One possibility is that UBQLN2 may be variably expressed in different sets of 
neurons, or potentially X chromosome inactivation due to somatic mosaicism may skew or 
influence either penetrance or neurodegenerative phenotype as previously postulated 
(Vengoechea et al., 2013, Teyssou et.al 2017). This is fuel for further investigation in UBQLN2 
mediated ALS/FTD. However, our study highlights the importance of proline-rich domain 
UBQLN2 mutations firstly as a rare contributor to ALS pathology and also to neurodegenerative 
pleiotropy.  
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Figure Legends 
Figure 1. Family pedigrees for affected individuals harbouring either the UBQLN2 P497H (A) or 
P506S (B) mutations. Probands are indicated by a block diagonal arrow. Affected individuals of 
the P497H family had a pure ALS phenotype in comparison to the P506S kindred whereby 
affected individuals manifested either FTD/ALS, ALS or HSP as indicated. (C) Both the P497H 
and P506S mutations are located in the PXX=proline rich domain of UBQLN (residues 491-
526). No mutations were found in the UBL=ubiquitin-like domain (33-103), or STI1=four heat-
shock-chaperonin-binding motifs (382-426), or the UBA=ubiquitin-associated domain (581-
620). (D) Both the P497H and P506S UBQLN2 mutations are fully conserved in mammals and 
rodents.  
Figure 2. Immunohistochemistry of cellular inclusions in post-mortem tissue from the 
ALS/FTD patient carrying the UBQLN2 P506S mutation. Staining for Ubiquilin 2 revealed 
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neuronal cytoplasmic inclusions positive for Ubiquilin 2 in the cerebral cortex and here in the 
dentate gyrus of the proband (A) whilst neuronal cytoplasmic inclusions positive for Ubiquilin 2 
were found in cases of sporadic FTLD-TDP, FTLD-ALS and here in an SALS case (B). No 
staining for Ubiquilin 2 was found in the dentate gyrus of control cases (C). Also, staining for 
pTDP-43 revealed neuronal cytoplasmic inclusions positive for pTDP-43 in the granular cell 
layer of dentate gyrus of hippocampus and upper layers of the frontal and temporal cortex of the 
proband (D-E). pTDP-43 positive neuronal cytoplasmic inclusions were also observed in the 
XIIth nerve nucleus (F). Scale bar (A-E)- 20µm, F-30 µm. 
Supplementary Table 1. A summary of all published UBQLN2 mutations to date. All mutations 
located within the PXX domain are bolded in red.  
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Highlights 
 
• We performed whole exome sequencing on 226 UK cases of familial 
amyotrophic lateral sclerosis (FALS) and frontotemporal dementia (FTD). 
 
• We identified 2 patients, each carrying a different mutation in the UBQLN2 
gene; P497H and P506S. 
 
• The P506S mutation segregated with disease in a family with behavioural 
variant FTD, spastic paraplegia and ALS. 
 
• Analysis of post mortem tissue from the index case revealed frequent neuronal 
UBQLN2 positive cytoplasmic inclusions in the dentate gyrus and TDP-43 
positive neuronal cytoplasmic inclusions in the frontal and temporal cortex 
and granular cell layer of the dentate gyrus of the hippocampus. 
 
• Significantly earlier age of onset was observed in male patients with mutations 
in the proline rich region of UBQLN2 after performing a comprehensive 
analysis of all published UBQLN2 mutations to date. 
